Higher MASLD regression in individuals with T2DM may be partly attributed to the use of glucose-lowering agents such as sodium-glucose cotransporter-2 inhibitors or glucagon-like peptide-1 receptor agonists, which can improve hepatic steatosis independently of lifestyle changes. Here, SLC5A2 is linked to fatty liver disease.